Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

CYP3A4 mutation causes vitamin D-dependent rickets type 3.

Roizen JD, Li D, O'Lear L, Javaid MK, Shaw NJ, Ebeling PR, Nguyen HH, Rodda CP, Thummel KE, Thacher TD, Hakonarson H, Levine MA.

J Clin Invest. 2018 Feb 20. pii: 98680. doi: 10.1172/JCI98680. [Epub ahead of print]

PMID:
29461981
2.

Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.

Khan BA, Robinson R, Fohner AE, Muzquiz LI, Schilling BD, Beans JA, Olnes MJ, Trawicki L, Frydenlund H, Laukes C, Beatty P, Phillips B, Nickerson D, Howlett K, Dillard DA, Thornton TA, Thummel KE, Woodahl EL.

Clin Transl Sci. 2018 Feb 13. doi: 10.1111/cts.12542. [Epub ahead of print]

PMID:
29436156
3.

P450 Pharmacogenetics in Indigenous North American Populations.

Henderson LM, Claw KG, Woodahl EL, Robinson RF, Boyer BB, Burke W, Thummel KE.

J Pers Med. 2018 Feb 1;8(1). pii: E9. doi: 10.3390/jpm8010009. Review.

4.

Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-sulfate, A Major Circulating Vitamin D Metabolite in Humans.

Wong T, Wang Z, Chapron BD, Suzuki M, Claw KG, Gao C, Foti RS, Prasad B, Chapron A, Calamia J, Chaudhry A, Schuetz EG, Horst RL, Mao Q, de Boer IH, Thornton TA, Thummel KE.

Drug Metab Dispos. 2018 Jan 17. pii: dmd.117.078428. doi: 10.1124/dmd.117.078428. [Epub ahead of print]

PMID:
29343609
5.

Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Tanner JA, Zhu AZ, Claw KG, Prasad B, Korchina V, Hu J, Doddapaneni H, Muzny DM, Schuetz EG, Lerman C, Thummel KE, Scherer SE, Tyndale RF.

Pharmacogenet Genomics. 2018 Jan;28(1):7-16. doi: 10.1097/FPC.0000000000000317.

PMID:
29232328
6.

Dietary Vitamin K and Association with Hepatic Vitamin K Status in a Yup'ik Study Population from Southwestern Alaska.

Au NT, Ryman T, Rettie AE, Hopkins SE, Boyer BB, Black J, Philip J, Yracheta J, Fohner AE, Reyes M, Thornton TA, Austin MA, Thummel KE.

Mol Nutr Food Res. 2018 Feb;62(3). doi: 10.1002/mnfr.201700746. Epub 2017 Dec 29.

PMID:
29094808
7.

Bi-cultural dynamics for risk and protective factors for cardiometabolic health in an Alaska Native (Yup'ik) population.

Philip J, Ryman TK, Hopkins SE, O'Brien DM, Bersamin A, Pomeroy J, Thummel KE, Austin MA, Boyer BB, Dombrowski K.

PLoS One. 2017 Nov 1;12(11):e0183451. doi: 10.1371/journal.pone.0183451. eCollection 2017.

8.

Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.

Xu M, Bhatt DK, Yeung CK, Claw KG, Chaudhry AS, Gaedigk A, Pearce RE, Broeckel U, Gaedigk R, Nickerson DA, Schuetz E, Rettie AE, Leeder JS, Thummel KE, Prasad B.

J Pharmacol Exp Ther. 2017 Nov;363(2):265-274. doi: 10.1124/jpet.117.243113. Epub 2017 Aug 17.

PMID:
28819071
9.

Simultaneous quantification of 25-hydroxyvitamin D3-3-sulfate and 25-hydroxyvitamin D3-3-glucuronide in human serum and plasma using liquid chromatography-tandem mass spectrometry coupled with DAPTAD-derivatization.

Gao C, Bergagnini-Kolev MC, Liao MZ, Wang Z, Wong T, Calamia JC, Lin YS, Mao Q, Thummel KE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Aug 15;1060:158-165. doi: 10.1016/j.jchromb.2017.06.017. Epub 2017 Jun 9.

PMID:
28622619
10.

Dietary and genetic influences on hemostasis in a Yup'ik Alaska Native population.

Au NT, Reyes M, Boyer BB, Hopkins SE, Black J, O'Brien D, Fohner AE, Yracheta J, Thornton T, Austin MA, Burke W, Thummel KE, Rettie AE.

PLoS One. 2017 Apr 4;12(4):e0173616. doi: 10.1371/journal.pone.0173616. eCollection 2017.

11.

CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations.

Hawkes CP, Li D, Hakonarson H, Meyers KE, Thummel KE, Levine MA.

J Clin Endocrinol Metab. 2017 May 1;102(5):1440-1446. doi: 10.1210/jc.2016-4048.

PMID:
28324001
12.

Association between iq'mik smokeless tobacco use and cardiometabolic risk profile among Yup'ik Alaska Native people.

Ryman TK, Boyer BB, Hopkins SE, Philip J, Thompson B, Beresford SAA, Thummel KE, Austin MA.

Ethn Health. 2017 Jan 24:1-15. doi: 10.1080/13557858.2017.1280136. [Epub ahead of print]

PMID:
28116909
13.

Implementing Precision Medicine: The Ethical Challenges.

Korngiebel DM, Thummel KE, Burke W.

Trends Pharmacol Sci. 2017 Jan;38(1):8-14. doi: 10.1016/j.tips.2016.11.007. Epub 2016 Dec 7. Review.

14.

Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors.

Tanner JA, Prasad B, Claw KG, Stapleton P, Chaudhry A, Schuetz EG, Thummel KE, Tyndale RF.

J Pharmacol Exp Ther. 2017 Jan;360(1):129-139. Epub 2016 Nov 4.

15.

Linkage and association analysis of circulating vitamin D and parathyroid hormone identifies novel loci in Alaska Native Yup'ik people.

Aslibekyan S, Vaughan LK, Wiener HW, Hidalgo BA, Lemas DJ, O'Brien DM, Hopkins SE, Stanhope KL, Havel PJ, Thummel KE, Boyer BB, Tiwari HK.

Genes Nutr. 2016 Aug 2;11:23. doi: 10.1186/s12263-016-0538-y. eCollection 2016.

16.

Development of a microphysiological model of human kidney proximal tubule function.

Weber EJ, Chapron A, Chapron BD, Voellinger JL, Lidberg KA, Yeung CK, Wang Z, Yamaura Y, Hailey DW, Neumann T, Shen DD, Thummel KE, Muczynski KA, Himmelfarb J, Kelly EJ.

Kidney Int. 2016 Sep;90(3):627-37. doi: 10.1016/j.kint.2016.06.011.

17.

Declines in traditional marine food intake and vitamin D levels from the 1960s to present in young Alaska Native women.

O'Brien DM, Thummel KE, Bulkow LR, Wang Z, Corbin B, Klejka J, Hopkins SE, Boyer BB, Hennessy TW, Singleton R.

Public Health Nutr. 2017 Jul;20(10):1738-1745. doi: 10.1017/S1368980016001853. Epub 2016 Jul 28.

18.

Prenatal pharmacogenomics: a promising area for research.

Dorfman EH, Cheng EY, Hebert MF, Thummel KE, Burke W.

Pharmacogenomics J. 2016 Aug;16(4):303-4. doi: 10.1038/tpj.2016.33. Epub 2016 May 10.

19.

Functional Comparison of Human Colonic Carcinoma Cell Lines and Primary Small Intestinal Epithelial Cells for Investigations of Intestinal Drug Permeability and First-Pass Metabolism.

Yamaura Y, Chapron BD, Wang Z, Himmelfarb J, Thummel KE.

Drug Metab Dispos. 2016 Mar;44(3):329-35. doi: 10.1124/dmd.115.068429. Epub 2015 Dec 23.

20.

Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Tracy TS, Chaudhry AS, Prasad B, Thummel KE, Schuetz EG, Zhong XB, Tien YC, Jeong H, Pan X, Shireman LM, Tay-Sontheimer J, Lin YS.

Drug Metab Dispos. 2016 Mar;44(3):343-51. doi: 10.1124/dmd.115.067900. Epub 2015 Dec 17. Review.

21.

Genetics, Diet, and Season Are Associated with Serum 25-Hydroxycholecalciferol Concentration in a Yup'ik Study Population from Southwestern Alaska.

Fohner AE, Wang Z, Yracheta J, O'Brien DM, Hopkins SE, Black J, Philip J, Wiener HW, Tiwari HK, Stapleton PL, Tsai JM, Thornton TA, Boyer BB, Thummel KE.

J Nutr. 2016 Feb;146(2):318-25. doi: 10.3945/jn.115.223388. Epub 2015 Dec 9.

22.

Tubular Secretion in CKD.

Suchy-Dicey AM, Laha T, Hoofnagle A, Newitt R, Sirich TL, Meyer TW, Thummel KE, Yanez ND, Himmelfarb J, Weiss NS, Kestenbaum BR.

J Am Soc Nephrol. 2016 Jul;27(7):2148-55. doi: 10.1681/ASN.2014121193. Epub 2015 Nov 27.

23.

Associations between diet and cardiometabolic risk among Yup'ik Alaska Native people using food frequency questionnaire dietary patterns.

Ryman TK, Boyer BB, Hopkins S, Philip J, Beresford SA, Thompson B, Heagerty PJ, Pomeroy JJ, Thummel KE, Austin MA.

Nutr Metab Cardiovasc Dis. 2015 Dec;25(12):1140-5. doi: 10.1016/j.numecd.2015.08.003. Epub 2015 Aug 21.

24.

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.

Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE.

Pharmacogenomics J. 2016 Aug;16(4):375-87. doi: 10.1038/tpj.2015.58. Epub 2015 Sep 1.

25.

The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.

Chaudhry AS, Prasad B, Shirasaka Y, Fohner A, Finkelstein D, Fan Y, Wang S, Wu G, Aklillu E, Sim SC, Thummel KE, Schuetz EG.

Drug Metab Dispos. 2015 Aug;43(8):1226-35. doi: 10.1124/dmd.115.064428. Epub 2015 May 28.

26.

Variability in Expression of CYP3A5 in Human Fetal Liver.

Vyhlidal CA, Pearce RE, Gaedigk R, Calamia JC, Shuster DL, Thummel KE, Leeder JS.

Drug Metab Dispos. 2015 Aug;43(8):1286-93. doi: 10.1124/dmd.115.064998. Epub 2015 May 15. Erratum in: Drug Metab Dispos. 2016 Sep;44(9):1459.

27.

Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.

Fohner AE, Robinson R, Yracheta J, Dillard DA, Schilling B, Khan B, Hopkins S, Boyer B, Black J, Wiener H, Tiwari HK, Gordon A, Nickerson D, Tsai JM, Farin FM, Thornton TA, Rettie AE, Thummel KE.

Pharmacogenet Genomics. 2015 Jul;25(7):343-353. doi: 10.1097/FPC.0000000000000143.

28.

Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.

Roth JA, Bradley K, Thummel KE, Veenstra DL, Boudreau D.

Pharmacoepidemiol Drug Saf. 2015 Jun;24(6):619-27. doi: 10.1002/pds.3769. Epub 2015 Apr 8.

29.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.

Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA.

Clin Pharmacol Ther. 2015 Jul;98(1):19-24. doi: 10.1002/cpt.113. Epub 2015 Jun 3.

30.

Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.

Tay-Sontheimer J, Shireman LM, Beyer RP, Senn T, Witten D, Pearce RE, Gaedigk A, Gana Fomban CL, Lutz JD, Isoherranen N, Thummel KE, Fiehn O, Leeder JS, Lin YS.

Pharmacogenomics. 2014 Dec;15(16):1947-62. doi: 10.2217/pgs.14.155. Erratum in: Pharmacogenomics. 2015 Jan;16(2):174. Pharmacogenomics. 2015 Jul;16(8):913.

31.

Identification of CYP3A7 for glyburide metabolism in human fetal livers.

Shuster DL, Risler LJ, Prasad B, Calamia JC, Voellinger JL, Kelly EJ, Unadkat JD, Hebert MF, Shen DD, Thummel KE, Mao Q.

Biochem Pharmacol. 2014 Dec 15;92(4):690-700. doi: 10.1016/j.bcp.2014.09.025. Epub 2014 Oct 22.

32.

Pharmacogenetic research in partnership with American Indian and Alaska Native communities.

Woodahl EL, Lesko LJ, Hopkins S, Robinson RF, Thummel KE, Burke W.

Pharmacogenomics. 2014 Jun;15(9):1235-41. doi: 10.2217/pgs.14.91.

33.

Maternal-fetal disposition of glyburide in pregnant mice is dependent on gestational age.

Shuster DL, Risler LJ, Liang CK, Rice KM, Shen DD, Hebert MF, Thummel KE, Mao Q.

J Pharmacol Exp Ther. 2014 Aug;350(2):425-34. doi: 10.1124/jpet.114.213470. Epub 2014 Jun 4.

34.

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.

Canestaro WJ, Austin MA, Thummel KE.

Genet Med. 2014 Nov;16(11):810-9. doi: 10.1038/gim.2014.41. Epub 2014 May 8. Review.

35.

Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trials.

de Boer IH, Sachs MC, Chonchol M, Himmelfarb J, Hoofnagle AN, Ix JH, Kremsdorf RA, Lin YS, Mehrotra R, Robinson-Cohen C, Siscovick DS, Steffes MW, Thummel KE, Tracy RP, Wang Z, Kestenbaum B.

Am J Kidney Dis. 2014 Aug;64(2):187-97. doi: 10.1053/j.ajkd.2014.02.015. Epub 2014 Apr 3.

36.

Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability.

Wang Z, Wong T, Hashizume T, Dickmann LZ, Scian M, Koszewski NJ, Goff JP, Horst RL, Chaudhry AS, Schuetz EG, Thummel KE.

Endocrinology. 2014 Jun;155(6):2052-63. doi: 10.1210/en.2013-2013. Epub 2014 Mar 18.

37.

Innovations in preclinical biology: ex vivo engineering of a human kidney tissue microperfusion system.

Kelly EJ, Wang Z, Voellinger JL, Yeung CK, Shen DD, Thummel KE, Zheng Y, Ligresti G, Eaton DL, Muczynski KA, Duffield JS, Neumann T, Tourovskaia A, Fauver M, Kramer G, Asp E, Himmelfarb J.

Stem Cell Res Ther. 2013;4 Suppl 1:S17. doi: 10.1186/scrt378. Epub 2013 Dec 20. Review.

38.

Sources of interindividual variability.

Thummel KE, Lin YS.

Methods Mol Biol. 2014;1113:363-415. doi: 10.1007/978-1-62703-758-7_17. Review.

PMID:
24523121
39.

Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.

Roth JA, Boudreau D, Fujii MM, Farin FM, Rettie AE, Thummel KE, Veenstra DL.

Clin Pharmacol Ther. 2014 Jun;95(6):636-43. doi: 10.1038/clpt.2014.26. Epub 2014 Feb 6.

40.

Why do most human liver cytosol preparations lack xanthine oxidase activity?

Barr JT, Choughule KV, Nepal S, Wong T, Chaudhry AS, Joswig-Jones CA, Zientek M, Strom SC, Schuetz EG, Thummel KE, Jones JP.

Drug Metab Dispos. 2014 Apr;42(4):695-9. doi: 10.1124/dmd.113.056374. Epub 2014 Jan 15.

41.

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

Yeung CK, Shen DD, Thummel KE, Himmelfarb J.

Kidney Int. 2014 Mar;85(3):522-8. doi: 10.1038/ki.2013.399. Epub 2013 Oct 16. Review.

42.

Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.

Fohner A, Muzquiz LI, Austin MA, Gaedigk A, Gordon A, Thornton T, Rieder MJ, Pershouse MA, Putnam EA, Howlett K, Beatty P, Thummel KE, Woodahl EL.

Pharmacogenet Genomics. 2013 Aug;23(8):403-14. doi: 10.1097/FPC.0b013e3283629ce9.

43.

Developing a prototype system for integrating pharmacogenomics findings into clinical practice.

Overby CL, Tarczy-Hornoch P, Kalet IJ, Thummel KE, Smith JW, Del Fiol G, Fenstermacher D, Devine EB.

J Pers Med. 2012 Nov 20;2(4):241-56. doi: 10.3390/jpm2040241.

44.

Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.

Shirasaka Y, Chang SY, Grubb MF, Peng CC, Thummel KE, Isoherranen N, Rodrigues AD.

Drug Metab Dispos. 2013 Aug;41(8):1566-74. doi: 10.1124/dmd.112.049940. Epub 2013 May 30.

45.

Tacrolimus placental transfer at delivery and neonatal exposure through breast milk.

Zheng S, Easterling TR, Hays K, Umans JG, Miodovnik M, Clark S, Calamia JC, Thummel KE, Shen DD, Davis CL, Hebert MF.

Br J Clin Pharmacol. 2013 Dec;76(6):988-96. doi: 10.1111/bcp.12122.

46.

CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.

Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE.

Transplantation. 2013 Mar 27;95(6):821-7. doi: 10.1097/TP.0b013e31827e6ad9.

47.
48.

Interpreting tacrolimus concentrations during pregnancy and postpartum.

Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG, Miodovnik M, Thummel KE, Easterling TR.

Transplantation. 2013 Apr 15;95(7):908-15. doi: 10.1097/TP.0b013e318278d367. Review.

49.

Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia.

Wang Z, Lin YS, Dickmann LJ, Poulton EJ, Eaton DL, Lampe JW, Shen DD, Davis CL, Shuhart MC, Thummel KE.

J Bone Miner Res. 2013 May;28(5):1101-16. doi: 10.1002/jbmr.1839.

50.

Gestational age-dependent changes in gene expression of metabolic enzymes and transporters in pregnant mice.

Shuster DL, Bammler TK, Beyer RP, Macdonald JW, Tsai JM, Farin FM, Hebert MF, Thummel KE, Mao Q.

Drug Metab Dispos. 2013 Feb;41(2):332-42. doi: 10.1124/dmd.112.049718. Epub 2012 Nov 21. Erratum in: Drug Metab Dispos. 2013 Mar;41(3):682.

Supplemental Content

Loading ...
Support Center